SynthesisRheumatology international2014
A meta-analysis of the association of IL-6 -174 G/C and -572 G/C polymorphisms with systemic lupus erythematosus risk.
Synthesis in Rheumatology international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association between interleukin gene polymorphisms and the risk of pneumoconiosis: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Association of IL-6 polymorphisms with hepatocellular carcinoma risk: evidences from a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Co-Occurrence of Endometriosis with Systemic Lupus Erythematosus: Genetic Aspects.International journal of molecular sciences · 2025Review
- Investigation of Interleukin-6 -572G/C Gene Polymorphism in Vitiligo Patients.Journal of clinical practice and research · 2025Article
- Frequency Evaluation of theInternational journal of molecular sciences · 2023Article
- Risk factors of systemic lupus erythematosus: an overview of systematic reviews and Mendelian randomization studies.Advances in rheumatology (London, England) · 2023Review
- Dysregulation of T Follicular Helper Cells in Lupus.Journal of immunology (Baltimore, Md. : 1950) · 2019Review
- Association between theInfection and drug resistance · 2017Review
- Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients.Journal of immunology research · 2016Article
- Interleukin 6 Accelerates Mortality by Promoting the Progression of the Systemic Lupus Erythematosus-Like Disease of BXSB.Yaa Mice.PloS one · 2016Article
- Association of interleukin-6 (-174 G/C) polymorphism with the prostate cancer risk: A meta-analysis.Biomedical reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The results from previous studies on association of IL-6 -174 G/C and -572 G/C polymorphisms with the risk of systemic lupus erythematosus (SLE) remained inconsistent. Therefore, a meta-analysis was performed to assess the association between these two polymorphisms and SLE susceptibility. A literature-based search was conducted to identify all relevant studies. Pooled data were estimated by fixed- and random-effects models when appropriate. Nine publications were included in the meta-analysis, seven for -174 G/C polymorphism and three for -572 G/C polymorphism. The results indicated that IL-6 -174 G/C polymorphism was significantly associated with SLE risk for recessive model and allele analysis in overall populations (OR 1.64, 95 % CI 1.10-2.45, P = 0.016; and 1.34, 1.05-1.72, P = 0.019, respectively, for recessive model and allele analysis) or in Caucasians (OR 1.37, 95 % CI 1.04-1.82, P = 0.027; and 1.27, 1.04-1.54, P = 0.018, respectively, for recessive model and allele analysis). Also, significant association between IL-6 -572 G/C polymorphism and SLE was found under recessive model (OR 1.49, 95 % CI 1.10-2.01, P = 0.009), but not under dominant model and allele analysis (OR 1.05, 95 % CI 0.77-1.43, P = 0.750; and 1.21, 1.00-1.48, P = 0.054, respectively, for dominant model and allele analysis). Additionally, our meta-analysis showed that IL-6 -174 G/C polymorphism was significantly associated with discoid skin lesions (P < 0.05). The present study indicates that IL-6 -174 G/C and -572 G/C polymorphisms could be candidates for susceptibility to SLE. Furthermore, a large number of studies should be performed to explore the association of IL-6 polymorphisms with the risk and clinical characteristics of SLE patients in different ethnics.
Indexed as
Identifiers
24013670What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.